Skip to content
HowShorted

Tarsus Pharmaceuticals, Inc. short interest in 2022

In 2022, Tarsus Pharmaceuticals, Inc.'s disclosed short interest ran from 1.56% of shares outstanding on 14 Jan 2022 to 3.89% on 30 Dec 2022, a change of +2.33 percentage points. The year's high was 6.36% on 15 Jul 2022 and its low 1.56% on 14 Jan 2022, averaging 3.74% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 25.21 days on 14 Oct 2022. Full history: Tarsus Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Tarsus Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
1.56% (14 Jan 2022)
End of year
3.89% (30 Dec 2022)
Change
+2.33 pp
High
6.36% (15 Jul 2022)
Low
1.56% (14 Jan 2022)
Average
3.74%
Highest days to cover
25.21 (14 Oct 2022)
SEC filings marked
8

Every report in 2022

Tarsus Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20221.56%18.45
31 Jan 20221.60%9.05
15 Feb 20221.70%10.18
28 Feb 20221.87%7.22
15 Mar 20221.95%16.3110-K filed, results (8-K)
31 Mar 20222.65%9.86
14 Apr 20222.84%17.52
29 Apr 20222.75%11.98
13 May 20221.87%1.00results (8-K), 10-Q filed
31 May 20222.11%2.62
15 Jun 20223.08%3.40
30 Jun 20225.90%3.78
15 Jul 20226.36%14.53
29 Jul 20226.14%17.60
15 Aug 20224.70%16.7910-Q filed, results (8-K)
31 Aug 20224.70%15.94
15 Sep 20224.69%13.55
30 Sep 20225.58%11.14
14 Oct 20225.64%25.21
31 Oct 20225.59%24.58
15 Nov 20224.77%9.7010-Q filed, results (8-K)
30 Nov 20224.60%13.49
15 Dec 20223.28%10.45
30 Dec 20223.89%7.13

See also: Tarsus Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.